Kodu・Aktsiate loetelu・AnaptysBio Inc

AnaptysBio Inc

Suletud

SektorTervishoid

53.16 -3.5

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

51.59

Max

55.13

Põhinäitajad
By Trading Economics
Sissetulek	-102M -53M
Müük	-83M 26M
Aktsiakasum	-1.843
Kasumimarginaal	-206.934
Töötajad	104
EBITDA	-99M -31M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+46.57% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	4. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-389M 1.6B
Eelmine avamishind	56.66
Eelmine sulgemishind	53.16

Uudiste sentiment

By Acuity

50%

162 / 340 Pingereas Healthcare

AnaptysBio Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

30. juuli 2026, 23:36 UTC

AnaptysBio Inc. shares declined after-market, reflecting ongoing weakness amid broader market volatility and the Federal Reserve's interest rate decisions.

29. juuli 2026, 19:56 UTC

Macro Event

AnaptysBio Inc shares are higher, recovering from an earlier dip, amid market volatility following the Federal Reserve's decision to maintain interest rates steady.

28. juuli 2026, 23:16 UTC

AnaptysBio Inc shares are higher in after-market trading, recovering from earlier lows. No specific news was identified to explain the movement.

24. juuli 2026, 19:16 UTC

AnaptysBio Inc shares are lower today, reflecting a decline since Thursday. Broader market sentiment is affected by recent volatility in oil prices.

23. juuli 2026, 09:16 UTC

AnaptysBio Inc is trading lower in pre-market hours amid broader market pressures from disappointing earnings reports and rising geopolitical tensions.

22. juuli 2026, 22:16 UTC

AnaptysBio Inc shares are higher in after-market hours, trading above Wednesday's close amid broader market concerns over rising crude oil prices and U.S.-Iran tensions.

21. juuli 2026, 20:12 UTC

AnaptysBio Inc. shares are lower in after-market trading, continuing a downward trend and positioning the stock below its 20-day moving average.

20. juuli 2026, 23:01 UTC

AnaptysBio Inc. shares are higher in after-market trading, reflecting routine activity. The stock remains below its 20-day moving average.

Võrdlus sarnastega

Hinnamuutus

AnaptysBio Inc Prognoos

Hinnasiht

By TipRanks

46.57% tõus

12 kuu keskmine prognoos

Keskmine 80.67 USD 46.57%

Kõrge 95 USD

Madal 70 USD

Põhineb 7 Wall Streeti analüütiku instrumendi AnaptysBio Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

7 ratings

Osta

Hoia

Müü

Põhineb 7 analüütiku instrumendi AnaptysBio Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

162 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.